IN2014DN06475A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06475A
IN2014DN06475A IN6475DEN2014A IN2014DN06475A IN 2014DN06475 A IN2014DN06475 A IN 2014DN06475A IN 6475DEN2014 A IN6475DEN2014 A IN 6475DEN2014A IN 2014DN06475 A IN2014DN06475 A IN 2014DN06475A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Herbert Stadler
Original Assignee
Stage Cell Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stage Cell Therapeutics Gmbh filed Critical Stage Cell Therapeutics Gmbh
Publication of IN2014DN06475A publication Critical patent/IN2014DN06475A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin or biotin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/405—Concentrating samples by adsorption or absorption
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN6475DEN2014 2012-02-23 2014-08-01 IN2014DN06475A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602150P 2012-02-23 2012-02-23
PCT/EP2013/053650 WO2013124474A2 (fr) 2012-02-23 2013-02-25 Isolement chromatographique de cellules et d'autres matériaux biologiques complexes

Publications (1)

Publication Number Publication Date
IN2014DN06475A true IN2014DN06475A (fr) 2015-06-12

Family

ID=47891608

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6475DEN2014 IN2014DN06475A (fr) 2012-02-23 2014-08-01

Country Status (11)

Country Link
US (4) US10228312B2 (fr)
EP (2) EP2817625B1 (fr)
JP (4) JP6362543B2 (fr)
CN (2) CN104254780B (fr)
AU (4) AU2013224027B2 (fr)
CA (1) CA2865033C (fr)
ES (1) ES3011307T3 (fr)
IN (1) IN2014DN06475A (fr)
RU (1) RU2746407C1 (fr)
SG (2) SG10201606970UA (fr)
WO (1) WO2013124474A2 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637719B2 (en) 2013-12-06 2017-05-02 Douglas T. Gjerde Devices and methods for purification of biological cells
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
AU2014368892B2 (en) 2013-12-20 2019-06-13 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
EP3126027A4 (fr) * 2014-04-03 2017-11-01 Douglas T. Gjerde Dispositifs et procédés de purification, de détection et d'utilisation de cellules biologiques
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
WO2015166049A1 (fr) 2014-04-30 2015-11-05 Iba Gmbh Procédé d'isolation d'une cellule cible
EP2955521A1 (fr) * 2014-06-11 2015-12-16 Centre Hospitalier Universitaire Vaudois (CHUV) Procédés pour séparer des cellules
CN113736828A (zh) * 2014-11-05 2021-12-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
DE202014105965U1 (de) 2014-12-10 2015-01-26 Cell.Copedia GmbH Spritzengehäuse zum Pipettieren eines biologischen Materials mit integrierten Membranen
WO2016166568A1 (fr) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Procédés, kits et appareil permettant d'augmenter une population de cellules
WO2016176652A2 (fr) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Cellules souches modifiées et leurs utilisations
CN105606815A (zh) * 2015-05-18 2016-05-25 烟台载通生物技术有限公司 一种用于免疫检测的多单元装置
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN108474791B (zh) * 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
GB201521784D0 (en) 2015-12-10 2016-01-27 Univ Birmingham Cell purification
WO2018023100A2 (fr) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anticorps anti-idiotypes et procédés associés
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
CN110072994A (zh) * 2016-12-23 2019-07-30 埃克波菲尔有限公司 用于纯化或分离微泡和外泌体的方法与组合物
CA3050085A1 (fr) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Conjugues de surface cellulaire et compositions cellulaires et methodes associees
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
KR20200064060A (ko) 2017-07-29 2020-06-05 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 세포 증폭용 시약
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
MA50855A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Procédé de génération de compositions thérapeutiques de cellules modifiées
CA3084445A1 (fr) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Procede de production d'une compositions de lymphocytes t modifies
EP3731947B1 (fr) 2017-12-29 2023-03-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Purification et marquage de vésicules extracellulaires à la aide d'une composition de résine à mode mixte
WO2019183334A1 (fr) * 2018-03-21 2019-09-26 Waters Technologies Corporation Préparation d'échantillon à base d'affinité élevée sans anticorps, sorbants, dispositifs et méthodes
MX2020014024A (es) 2018-06-18 2021-03-09 Exopharm Ltd Metodos y composiciones para la purificacion o aislamiento de microvesiculas y exosomas.
EP3824088A1 (fr) 2018-07-17 2021-05-26 University of Washington Compositions et procédés associés à une sélection de cellules réversible fondée sur un aptamère
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
MX2021002574A (es) 2018-09-11 2021-06-08 Juno Therapeutics Inc Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
EP3874024A1 (fr) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Procédés de sélection et de stimulation de cellules et appareil associé
JP7604366B2 (ja) 2018-11-06 2024-12-23 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作されたｔ細胞を作製するための方法
MX2021015125A (es) 2019-06-07 2022-04-06 Juno Therapeutics Inc Cultivo automatizado de celulas t.
WO2020260949A2 (fr) * 2019-06-27 2020-12-30 Bioimmunate Technologies Ltd. Dispositifs, systèmes et procédés d'élimination de composants de liquides biologiques
EP4022637A2 (fr) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Procédés d'apprentissage automatique pour la classification de cellules
AU2020337450A1 (en) * 2019-08-30 2022-03-03 Flodesign Sonics, Inc. Acoustic affinity cell selection for multiple target receptors
EP4028159A1 (fr) * 2019-09-10 2022-07-20 Pierce Biotechnology, Inc. Compositions, dispositifs, systèmes et procédés de préparation d'échantillon
WO2021084050A1 (fr) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Dispositifs de sélection et/ou stimulation de cellules et procédés d'utilisation
US20230019849A1 (en) * 2019-12-09 2023-01-19 St. Jude Children's Research Hospital, Inc. Method for Preparing CD7-Negative, CD3-Positive T Cells
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
JP7502451B2 (ja) * 2020-01-31 2024-06-18 セル．コペディア ゲーエムベーハー 生物学的実体を単離する方法
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
IL295384B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
WO2023017115A1 (fr) * 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionnement de cellules sur la base d'une protéine de marquage
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
WO2023147510A1 (fr) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Réseaux de chromatographie et méthodes et kits associés
ES3024941T3 (en) * 2022-02-02 2025-06-05 Sartorius Bia Separations D O O Method of purifying or removing a target component from full plasma
WO2023213969A1 (fr) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Protéine de liaison virale et réactifs, articles et méthodes d'utilisation associés
EP4532695A1 (fr) 2022-05-25 2025-04-09 Celgene Corporation Procédés de fabrication de thérapies par lymphocytes t
EP4615960A1 (fr) 2022-11-09 2025-09-17 C3S2 GmbH Procédés de fabrication de cellules immunitaires modifiées
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
WO2024182516A1 (fr) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Thérapie cellulaire pour le traitement de maladies auto-immunes systémiques
CN122029170A (zh) 2023-08-25 2026-05-12 朱诺治疗学股份有限公司 基于桥环的dna依赖性蛋白激酶抑制剂和组合物及其在基因编辑中的应用
WO2025049254A1 (fr) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Inhibiteurs à base de pyrazolopyridine de protéine kinase dépendante de l'adn et compositions et application dans l'édition génique
WO2025049250A1 (fr) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Inhibiteurs à base de silacycle à noyau 6,6 de protéine kinase dépendante de l'adn et compositions et application dans l'édition génique
WO2025049247A1 (fr) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Inhibiteurs à base de silacycle à noyau 5,6 de protéine kinase dépendante de l'adn et compositions et application dans l'édition génique
AU2024364039A1 (en) 2023-10-18 2026-04-16 Tq Therapeutics Gmbh A method of manufacturing a cellular therapy product and respective kits and devices
US12434218B2 (en) 2023-11-28 2025-10-07 Phenomenex, Inc. Pore structure for separation of adeno-associated viruses (AAVS) from their aggregates
WO2025160395A1 (fr) 2024-01-25 2025-07-31 Juno Therapeutics, Inc. Utilisation d'inhibiteurs de protéine kinase dépendants de l'adn à cycle ponté en association avec un inhibiteur de l'adn polymérase thêta et compositions et application dans l'édition génique
WO2025179188A1 (fr) 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Inhibiteurs à base de pyrazole de protéine kinase dépendante de l'adn et compositions et applications dans l'édition génique
TW202605143A (zh) 2024-05-10 2026-02-01 美商奇諾治療有限公司 表現cd19嵌合抗原受體(car)之基因工程化t細胞及其用於同種異體細胞療法之用途
WO2026020055A2 (fr) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Procédés d'évaluation d'exosomes dans une composition cellulaire et utilisations associées
EP4699628A1 (fr) 2024-08-21 2026-02-25 Fenwal, Inc. Chambre de sélection de cellules et procédés de sélection de cellules
EP4725578A1 (fr) 2024-10-08 2026-04-15 TQ Therapeutics GmbH Conceptions de colonne pour chromatographie d'affinité

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2467434A (en) 1947-05-10 1949-04-19 Air Associates Inc Servomotor and pressure responsive valve therefor
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3583940D1 (de) 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
EP0997477B1 (fr) 1994-07-29 2006-03-15 Sunol Molecular Corporation MHC-complexes et leurs applications
WO1996023879A1 (fr) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Corps agglutinants - multiplicite de proteines capables de lier diverses petites molecules
WO1996024606A1 (fr) 1995-02-09 1996-08-15 University Of Washington Streptavidine a affinite modifiee
AU5917796A (en) * 1995-04-11 1997-04-09 Trustees Of Boston University Streptavidin mutants
US5629205A (en) 1995-05-19 1997-05-13 Allelix Biopharmaceuticals Inc. Promoters for gene expression
WO1997005266A1 (fr) 1995-07-25 1997-02-13 Introgene B.V. Procedes et moyens d'apport cible de genes
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US5773224A (en) 1996-02-12 1998-06-30 Grandics; Peter Immunoselection system for cell elution
DE19637718A1 (de) 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
US6022688A (en) 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
ATE272070T1 (de) 1996-08-16 2004-08-15 Harvard College Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998040396A1 (fr) 1997-03-14 1998-09-17 Trustees Of Boston University Streptavidine a aromes multiples
US6391571B1 (en) 1997-04-01 2002-05-21 Roche Diagnostics Gmbh Recombinant inactive avidin mutants
DK1017721T3 (da) 1997-09-16 2009-04-20 Univ Oregon Health & Science Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US5985658A (en) * 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
WO1999042597A1 (fr) 1998-02-19 1999-08-26 President And Fellows Of Harvard College Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes
US6664042B1 (en) 1999-01-26 2003-12-16 Cornell Research Foundation, Inc. Determining viral load in double negative T cells
WO2000046349A1 (fr) 1999-02-04 2000-08-10 Technion Research & Development Foundation Ltd. Methode et appareil de renouvellement et de multiplication de cellules souches hematopoietiques et/ou de progeniteurs
EP1048732A1 (fr) 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Procédé de préparation des protéine secretées sous une forme pliée naturelle
US6849185B1 (en) 1999-05-14 2005-02-01 Pall Corp Charged membrane
DE60027291T2 (de) 1999-05-14 2007-01-18 Pall Corp. Elektrisch geladene membran
EP1669129A1 (fr) 1999-05-14 2006-06-14 Pall Corporation Membrane électriquement chargée
ATE458818T1 (de) 1999-06-07 2010-03-15 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
WO2001081371A1 (fr) 2000-04-25 2001-11-01 Otsuka Pharmaceutical Co., Ltd. Peptides gd3 mimetiques
US6638728B1 (en) 2000-06-16 2003-10-28 Pierce Biotechnology, Inc. Coated surfaces with high capacity for capturing target molecules
CA2426100A1 (fr) 2000-11-03 2002-05-23 Genentech, Inc. Decalages du rythme metabolique dans des fermentations exprimant des proteines de recombinaison
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
EP1227321A1 (fr) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Purification fonctionelle de lymphocytes T antigène-spécifiques par marquage réversible aux multimères MHC
WO2002055992A2 (fr) 2001-01-12 2002-07-18 Becton Dickinson Co Proteines de fusion mhc auto-multimerisantes et intrinsequement fluorescentes et complexes formes de ces proteines
GB0102568D0 (en) 2001-02-01 2001-03-21 Magnetic Biosolutions Sweden A Method
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
EP1908769A1 (fr) 2001-08-27 2008-04-09 Genentech, Inc. Système d'expression d'anticorps et ensemble
CN100513414C (zh) 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
JP2005536184A (ja) * 2002-03-01 2005-12-02 エルドマン，ヴォルカー，エー． ストレプトアビジン結合ペプチド
US7754155B2 (en) * 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
AU2003234194A1 (en) 2002-04-23 2003-11-10 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
JP4659453B2 (ja) 2002-06-24 2011-03-30 ハイグロス・インヴェスト・ゲゼルシャフト・ミット・ベシュレンクトル・ハフツング エンドトキシンを検出および除去する方法
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
CA2500392C (fr) 2002-09-27 2012-11-27 The General Hospital Corporation Dispositif microfluidique pour la separation de cellules et utilisations de ce dispositif
EP1588166A4 (fr) 2003-01-09 2007-06-27 Macrogenics Inc Systeme vectoriel a double expression servant a exprimer des anticorps dans des cellules bacteriennes et mammiferes
WO2004096975A2 (fr) 2003-05-02 2004-11-11 Insception Bioscience, Inc. Appareil et procedes pour l'amplification du nombre de cellules sanguines souche
DE60334250D1 (de) 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
US7943393B2 (en) * 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
WO2005017174A2 (fr) 2003-08-13 2005-02-24 Sandoz Ag Procédé de purification de polypeptides recombinés
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
GB2408507B (en) 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
KR100570422B1 (ko) 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
WO2005050209A1 (fr) 2003-11-20 2005-06-02 Biosensor Applications Sweden (Publ) Melange d'au moins deux anticorps differents, specifiques d'antigenes predetermines, et utilisation de ce melange
CN1882605B (zh) 2003-11-21 2012-07-11 陶氏环球技术公司 使用Sec-系统分泌的改进的表达系统
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
ES2527291T3 (es) 2004-03-11 2015-01-22 Genentech, Inc. Proceso para la producción de polipéptidos
US7776583B2 (en) * 2004-06-03 2010-08-17 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
JP5255841B2 (ja) 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク 競合示差スクリーニング
WO2006058226A2 (fr) 2004-11-24 2006-06-01 The Trustees Of Boston University Streptavidines dimeres modifiees et leurs utilisations
US20060252087A1 (en) * 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
US7704708B2 (en) 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2007117602A2 (fr) 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation et utilisation de lymphocytes t regulateurs humains
US20070238169A1 (en) 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
EP1903105B1 (fr) 2006-09-22 2010-04-21 Wacker Chemie AG Procédé pour la production de protéines par fermentation
DK1903115T3 (da) 2006-09-22 2011-05-23 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af antistoffer
DK1905839T4 (da) 2006-09-22 2019-10-07 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af proteiner
EP2687540A1 (fr) 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Vaccins de peptide pour cancers exprimant les polypeptides MPHOSPH1 ou DEPDC1
EP2085782B1 (fr) * 2006-11-02 2017-03-08 Kyowa Medex CO., LTD. Procédé d'essai immunologique d'un composant à mesurer
EP2518193A3 (fr) * 2006-11-15 2013-01-23 Invitrogen Dynal AS Procedes pour lier de facon reversible un compose de Biotine a un support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) * 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
CA2677179C (fr) 2007-01-31 2016-02-16 Dow Global Technologies Inc. Sequences leader bacteriennes pour augmenter l'expression
KR20080076622A (ko) 2007-02-16 2008-08-20 포항공과대학교 산학협력단 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법
US8709980B2 (en) 2007-03-26 2014-04-29 Celexion, Llc Cell surface display, screening and production of proteins of interest
EP2155782A2 (fr) 2007-03-26 2010-02-24 Dako Denmark A/S Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses
EP2167537A2 (fr) 2007-07-03 2010-03-31 Dako Denmark A/S Procedes compiles pour analyser et trier des echantillons
CN101802195B (zh) 2007-08-20 2012-10-24 内克斯特伊拉股份公司 pⅦ噬菌体展示
JP4962215B2 (ja) 2007-08-28 2012-06-27 パナソニック株式会社 墨出し器の精度確認装置及び墨出し器の精度確認方法
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
EP3358354B1 (fr) * 2008-01-18 2020-07-15 President and Fellows of Harvard College Procédés de détection de signatures de maladies ou d'états dans des fluides corporels
ES2666667T3 (es) 2008-01-29 2018-05-07 Fred Hutchinson Cancer Research Center Identificación de células T CD8+ que son CD161 hi y/o IL-18R (alfa) hi y tienen una capacidad de evacuación rápida de fármacos
CN106986926A (zh) 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP2254592B1 (fr) 2008-02-28 2019-06-05 Dako Denmark A/S Multimères de mhc dans le diagnostic et le traitement de la borréliose
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (fr) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Transduction virale assistée par des billes
DE102009018647A1 (de) 2009-04-23 2010-10-28 Osram Opto Semiconductors Gmbh Strahlungsemittierende Vorrichtung
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
WO2011053971A2 (fr) 2009-11-02 2011-05-05 Fina Biosolutions, Llc Procédé d'amélioration de sensibilité d'analyses à base d'anticorps
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
US8450086B2 (en) 2009-11-17 2013-05-28 Centocor Ortho Biotech Inc. Bacterial membrane protein secretion
US20120321665A1 (en) 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
US9637719B2 (en) 2013-12-06 2017-05-02 Douglas T. Gjerde Devices and methods for purification of biological cells
US9370732B2 (en) 2013-02-15 2016-06-21 Douglas T. Gjerde Methods for purifying biological cells
US9242244B2 (en) 2010-02-09 2016-01-26 Douglas T. Gjerde Method and apparatus for pipette tip columns
US9891148B2 (en) 2010-02-09 2018-02-13 Douglas T. Gjerde Method and apparatus for pipette tip columns
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
EP2363501A1 (fr) * 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Nanocomposites dotés d'une homogénéité améliorée
JP5665021B2 (ja) 2010-03-08 2015-02-04 国立大学法人東京農工大学 融合ｍｈｃ分子連結磁気微粒子、抗原ペプチドのスクリーニング方法、組換えベクター、及び磁性細菌の形質転換体
WO2011161086A2 (fr) 2010-06-23 2011-12-29 Stobbe Tech. A/S Dispositif et procédé pour la culture industrielle de cellules
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
EP2982766B1 (fr) * 2010-08-06 2018-05-23 Ludwig-Maximilians-Universität München Identification d'antigènes cible de lymphocytes t
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
WO2012058627A2 (fr) 2010-10-29 2012-05-03 Miqin Zhang Système de nanoparticules préciblées et procédé de marquage de particules biologiques
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
JP5840857B2 (ja) 2011-04-08 2016-01-06 国立大学法人 東京大学 細胞傷害性ｔ細胞誘導用組成物
US9023604B2 (en) 2011-07-18 2015-05-05 Iba Gmbh Method of reversibly staining a target cell
WO2013038272A2 (fr) 2011-09-13 2013-03-21 Uti Limited Partnership Mutéine streptavidine présentant une liaison réversible pour une biotine, et protéines marquées par un peptide de liaison à la streptavidine
WO2013062365A2 (fr) 2011-10-26 2013-05-02 국립암센터 Lymphocyte t transfecté par un gène ctla4 mutant et composition en contenant pour immunothérapie anticancéreuse
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CN112375846A (zh) 2012-07-13 2021-02-19 宾夕法尼亚大学董事会 评估用于施用的转导t细胞的适用性的方法
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
EP2711418B1 (fr) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Procédé de stimulation polyclonales de lymphocyte T par nanomatrices flexibles
CA2891820A1 (fr) 2012-11-16 2014-05-22 Iba Gmbh Muteines de streptavidine et procedes d'utilisation associes
EP2951192A1 (fr) 2013-01-31 2015-12-09 Glaxo Group Limited Procédé de production de protéine
US10220332B2 (en) 2013-02-15 2019-03-05 Douglas T. Gjerde Columns for isolation, detection and use of biological cells
US10107729B2 (en) 2013-02-15 2018-10-23 Douglas T. Gjerde Isolation, detection and use of biological cells
US9920294B2 (en) 2013-02-15 2018-03-20 Douglas T. Gjerde Devices and methods for purification, detection and use of biological cells
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
AU2014368892B2 (en) 2013-12-20 2019-06-13 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
WO2015162211A1 (fr) 2014-04-24 2015-10-29 Miltenyi Biotec Gmbh Procédé de production automatisée de cellules t génétiquement modifiées
EP3738597A1 (fr) 2014-04-25 2020-11-18 Bluebird Bio, Inc. Procédés améliorés de production de thérapies reposant sur des cellules adoptives
WO2015166049A1 (fr) 2014-04-30 2015-11-05 Iba Gmbh Procédé d'isolation d'une cellule cible
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
EP3511413B1 (fr) 2014-07-25 2022-09-07 Theravectys Vecteurs lentiviraux pour l'expression régulée d'une molécule de récepteur d'antigène chimérique
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
WO2016166568A1 (fr) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Procédés, kits et appareil permettant d'augmenter une population de cellules
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
CA3020330A1 (fr) 2016-04-07 2017-10-12 Bluebird Bio, Inc. Compositions de lymphocytes t recepteurs d'antigenes chimeriques
CA3050085A1 (fr) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Conjugues de surface cellulaire et compositions cellulaires et methodes associees
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
US20190247846A1 (en) 2018-02-09 2019-08-15 Chris Suh Method and Apparatus for Pipette Tip Columns
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EP3874024A1 (fr) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Procédés de sélection et de stimulation de cellules et appareil associé

Also Published As

Publication number Publication date
JP2021090471A (ja) 2021-06-17
EP2817625A2 (fr) 2014-12-31
JP6362543B2 (ja) 2018-07-25
US12135265B2 (en) 2024-11-05
AU2021282451B2 (en) 2025-02-20
JP2023016981A (ja) 2023-02-02
RU2746407C1 (ru) 2021-04-13
JP2015512621A (ja) 2015-04-30
US12066365B2 (en) 2024-08-20
CA2865033C (fr) 2021-11-02
SG10201606970UA (en) 2016-10-28
EP2817625B1 (fr) 2025-01-01
US20150024411A1 (en) 2015-01-22
CN104254780B (zh) 2017-04-12
WO2013124474A3 (fr) 2013-12-05
CA2865033A1 (fr) 2013-08-29
SG11201404991YA (en) 2014-09-26
AU2019200178B2 (en) 2021-09-09
EP4545964A3 (fr) 2025-10-01
JP7192014B2 (ja) 2022-12-19
JP7710427B2 (ja) 2025-07-18
CN104254780A (zh) 2014-12-31
AU2025200426A1 (en) 2025-02-27
JP6857626B2 (ja) 2021-04-14
AU2019200178A1 (en) 2019-01-31
US20250020556A1 (en) 2025-01-16
CN106940268B (zh) 2021-09-21
ES3011307T3 (en) 2025-04-07
EP4545964A2 (fr) 2025-04-30
HK1202335A1 (en) 2015-09-25
US20190226951A1 (en) 2019-07-25
AU2021282451A1 (en) 2022-01-06
US10228312B2 (en) 2019-03-12
US20190234844A1 (en) 2019-08-01
CN106940268A (zh) 2017-07-11
WO2013124474A2 (fr) 2013-08-29
AU2013224027B2 (en) 2019-01-24
JP2018108103A (ja) 2018-07-12
AU2013224027A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
BR112014017614A2 (fr)
BR112014017625A2 (fr)
BR112014017592A2 (fr)
BR112014017607A2 (fr)
BR112014018837A2 (fr)
BR112014017646A2 (fr)
BR112014017638A2 (fr)
AR092201A1 (fr)
BR112013027865A2 (fr)
BR112014017644A2 (fr)
BR112014017634A2 (fr)
BR112014017647A2 (fr)
BR112014022767A2 (fr)
BR112014013184A8 (fr)
BR112014017618A2 (fr)
BR112014017627A2 (fr)
BR112014017623A2 (fr)
BR112014017652A2 (fr)
BR112014017630A2 (fr)
BR112014017621A2 (fr)
BR112014017631A2 (fr)
BR112014017622A2 (fr)
BR112014019573A2 (fr)
BR112014017671A2 (fr)
BR112014017589A2 (fr)